R
Rita Moretti
Researcher at University of Trieste
Publications - 137
Citations - 3891
Rita Moretti is an academic researcher from University of Trieste. The author has contributed to research in topics: Dementia & Vascular dementia. The author has an hindex of 32, co-authored 130 publications receiving 3394 citations.
Papers
More filters
Journal ArticleDOI
A longitudinal study of brain atrophy and cognitive disturbances in the early phase of relapsing-remitting multiple sclerosis.
Robert Zivadinov,Juraj Sepčić,D. Nasuelli,R. De Masi,L Monti Bragadin,Maria Antonietta Tommasi,S Zambito-Marsala,Rita Moretti,Alessio Bratina,Maja Ukmar,Roberto Pozzi-Mucelli,Attilio Grop,Giuseppe Cazzato,Marino Zorzon +13 more
TL;DR: In the early phase of relapsing-remitting multiple sclerosis the cognitive deterioration relies more on the development of brain parenchymal volume atrophy than on the extent of burden of disease in the brain.
Journal ArticleDOI
Sexual dysfunction in multiple sclerosis: a case-control study. I. Frequency and comparison of groups.
Marino Zorzon,Robert Zivadinov,A. Bosco,L Monti Bragadin,Rita Moretti,L Bonfigli,P Morassi,L G Iona,Giuseppe Cazzato +8 more
TL;DR: The findings suggest that a peculiar damage of the structures involved in sexual function is responsible for the dysfunction in patient with multiple scerosis, but the highly significant lower frequency of symptoms of depression and anxiety in healthy controls may also imply a possible causative role of psychological factors.
Journal ArticleDOI
Frontotemporal dementia: paroxetine as a possible treatment of behavior symptoms. A randomized, controlled, open 14-month study.
TL;DR: Patients aged 64–68 years, with a diagnosis of FTD, were randomized to receive paroxetine up to 20 mg/day or piracetam up to 1,200 mg/ day and showed significant improvements in behavioral symptoms, reflected by a reduction of caregiver stress.
Journal ArticleDOI
The Controversial Role of Homocysteine in Neurology: From Labs to Clinical Practice.
Rita Moretti,Paola Caruso +1 more
TL;DR: The possible role of HHcy in neurodegenerative disease and stroke is reviewed to understand its pathogenesis and whether patients should be routinely screened for homocysteine.
Journal ArticleDOI
Rivastigmine in frontotemporal dementia: an open-label study.
Rita Moretti,Paola Torre,Rodolfo M. Antonello,Tatiana Cattaruzza,Giuseppe Cazzato,Antonio Bava +5 more
TL;DR: Rivastigmine-treated patients were less behaviourally impaired, and caregiver burden was reduced, at 12 months, compared with baseline, and the use of cholinesterase inhibitors in FTD warrants further research.